Search Results

You are looking at 51 - 60 of 257 items for :

  • endocrine trends x
  • Open access x
Clear All
Open access

A Rehfeld, D L Egeberg, K Almstrup, J H Petersen, S Dissing and N E Skakkebæk

Introduction Human male infertility is a common problem worldwide ( 1 ). The causes are in many cases unknown, but exposure to endocrine disrupting chemicals (EDCs) has been suspected to be involved ( 2 , 3 ). Sperm cell dysfunction is a

Open access

Yuan Fang, Xuehong Zhang, Huilin Xu, Stephanie A Smith-Warner, Dongli Xu, Hong Fang and Wang Hong Xu

district. Restricted cubic splines functions (RCS) was used to describe the incidence trend of all cancers along with age and period of observation ( 16 ). All data analyses were performed using SAS, version 9.2 for windows (SAS Institute). All tests were

Open access

Signe Frøssing, Malin Nylander, Caroline Kistorp, Sven O Skouby and Jens Faber

differences between treatment groups over time showed a change in MR-proANP of −25% (95% CI −37 to −11, P  = 0.001), a trend in MR-proADM of −6% (95% CI −11 to 2, P  = 0.057) and no change in levels of copeptin in the liraglutide group compared with placebo

Open access

Ana P Estrada-Flórez, Mabel E Bohórquez, Alejandro Vélez, Carlos S Duque, Jorge H Donado, Gilbert Mateus, Cesar Panqueba-Tarazona, Guadalupe Polanco-Echeverry, Ruta Sahasrabudhe, Magdalena Echeverry and Luis G Carvajal-Carmona

differences between the CVPTC and FVPTC subtypes ( Table 1 ). However, we found a trend where CVPTCs, relative to FVPTCs, had a higher frequency of high-risk features, such as vascular invasion (32 vs 21%, P  = 0.052, Table 1 ) or lymph node metastasis (39

Open access

Soraya Puglisi, Paola Perotti, Mattia Barbot, Paolo Cosio, Carla Scaroni, Antonio Stigliano, Pina Lardo, Valentina Morelli, Elisa Polledri, Iacopo Chiodini, Giuseppe Reimondo, Anna Pia and Massimo Terzolo

Clinical Trial database (EudraCT number: 2013-002063-26). The patients volunteered for the study and gave their written informed consent. The study is reported according to the Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) ( 10

Open access

Prachi Bansal, Anurag Lila, Manjunath Goroshi, Swati Jadhav, Nilesh Lomte, Kunal Thakkar, Atul Goel, Abhidha Shah, Shilpa Sankhe, Naina Goel, Neelam Jaguste, Tushar Bandgar and Nalini Shah

with microadenoma were compared to those with macroadenoma. The patients with early remission had a significantly lower recurrence rate (30.8% vs 61.5%, P  = 0.001), with a trend towards later time to recurrence (mean time to recurrence of 41.9 ± 26

Open access

Samira M Sadowski, Emanuel Christ, Benoit Bédat, Attila Kollár, Wolfram Karenovics, Aurel Perren, Frédéric Triponez and on behalf of the SwissNET registry

Cushing’s syndrome and the others had TC syndrome), with an additional patient with multiple endocrine neoplasia type 1 (MEN1). The mean interval between symptoms and diagnosis was 6 ± 9.9 months. Overall, the follow-up time was 30.2 ± 23.1 months, ranging

Open access

Huy Gia Vuong, Nguyen Phuoc Long, Nguyen Hoang Anh, Tran Diem Nghi, Mai Van Hieu, Le Phi Hung, Tadao Nakazawa, Ryohei Katoh and Tetsuo Kondo

Introduction Thyroid cancer is the most common endocrine cancer, and its incidence has been steadily increasing over the last few decades ( 1 ). There are several subtypes of thyroid carcinoma: papillary, follicular, poorly differentiated

Open access

Xiao-jun Zhou, Lin Ding, Jia-xin Liu, Le-qun Su, Jian-jun Dong and Lin Liao

Introduction Diabetes, as one of the largest global health emergencies in the 21st century, has increased with a burgeoning trend. The latest International Diabetes Federation (IDF) Diabetes Atlas indicated that in 2016 the estimated number of

Open access

Wafaa M Rashed, Anas Saad, Muneer Al-Husseini, Ahmed Mahmoud Galal, Assem Mohamed Ismael, Ahmed M Al-Tayep, Ayman El Shafie, Mahmoud Ahmed Ali and Ahmad Samir Alfaar

Introduction The adrenal gland malignancies are extremely sporadic and heterogeneous. It represents 3.6% of endocrine glands cancers ( 1 ). Adrenal malignancies can be either primary adrenal tumors or secondary metastases, with metastases